This pilot registry study suggests that 'primary' (idiopathic) sarcopenia can be reduced in otherwise healthy subjects with supplementation of Robuvit®, which increased hand strength, muscular vascularization, subjective vigor and reduced plasma oxidative stress and urinary excretion of 3-methylhistidine after 3 months.
Key Findings
Results
Body fat percentage decreased significantly in the Robuvit® supplement group compared to controls after 3 months.
Study population: 60 male subjects aged 70-80 years with loss of muscular mass and strength
30 subjects received Robuvit® 300 mg/day (3 capsules/day) and 30 served as controls
Both groups received standard management (SM); the treatment group received SM+Robuvit®
Difference was statistically significant (P<0.05)
Duration of supplementation was 3 months
Results
Hand grip strength was significantly increased in the Robuvit®-supplemented subjects compared to controls.
Hand strength was measured using hand grip dynamometry
The increase was statistically significant (P<0.05)
Study included 30 subjects in the supplement group and 30 controls
Both groups were described as comparable at baseline
Results
Muscular vascularization improved significantly in the Robuvit® supplemented group compared to controls.
Muscular vascularization was assessed using laser Doppler flowmetry
Improvement was statistically significant (P<0.05)
Assessment was conducted after 3 months of supplementation
Results
Subjective perception of vigor significantly increased in subjects using Robuvit® compared to controls.
Difference was statistically significant (P<0.05)
This was a subjective outcome measure reported by the 30 supplemented subjects
Robuvit® is noted to be used in several conditions including convalescence, fatigue, and vigor loss
Results
Plasma oxidative stress was significantly decreased in the Robuvit® group compared to controls after 3 months.
Reduction in plasma oxidative stress was statistically significant (P<0.05)
Assessment was conducted after 3 months of supplementation at 300 mg/day
Study population consisted of 60 male subjects aged 70-80 years
Results
Urinary excretion of 3-methylhistidine (3MEH) significantly decreased in the Robuvit® group compared to controls, suggesting reduced muscle breakdown.
Decrease in urinary 3-methylhistidine was statistically significant (P<0.05)
3-methylhistidine is described as 'a marker of muscle loss'
The reduction suggests 'a reduced level of muscle breakdown' per the authors
Measurement was taken after 3 months of supplementation
Results
Tolerability of Robuvit® supplementation at 300 mg/day over 3 months was reported as very good.
Tolerability was described as 'very good'
30 male subjects received 300 mg/day (3 capsules/day) for 3 months
Subjects were described as 'otherwise healthy' with sarcopenia
Belcaro G, Cesarone M, Dugall M, Bavera P, Ledda A, Scipione C, et al.. (2026). Sarcopenia: effects of Robuvit® supplementation on loss of muscular mass and strength.. Minerva medica. https://doi.org/10.23736/S0026-4806.25.09735-6